Novo Nordisk agreed to a licensing arrangement with Nanexa for a long-acting injectable drug-delivery technology, with deal value reported at up to €1.165 billion (about $1.325 billion). The partnership targets improved duration for peptide-based cardiometabolic medicines, including obesity and type 2 diabetes products. The agreement is designed as a global exclusive license for Nanexa’s platform, extending Novo’s strategy to lengthen dosing intervals and reduce injection frequency. For the field, drug-delivery upgrades remain a core lever in differentiating GLP-1 and related therapies as competition intensifies. Deal terms also signal that delivery innovation is being valued almost like a clinical asset—particularly when it can translate into better adherence and potential cost-benefit advantages. With long-acting formulations now a central battleground, this contract further tightens the link between delivery platforms and blockbuster cardiometabolic franchises.